Receive a FREE Mesothelioma Treatment
Information Packet

Mesothelioma

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Background:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab can locate tumor cells and kill them without harming normal cells. It is not yet known if combination chemotherapy is more effective with or without bevacizumab in treating malignant mesothelioma. Randomized phase II trial to compare the effectiveness of combination chemotherapy with or without bevacizumab in treating patients who have malignant mesothelioma.

Inclusion Criteria:
Histologically or cytologically confirmed malignant pleural or peritoneal mesothelioma that is not amenable to curative surgery.

Location/Contact Information:
California
City of Hope Comprehensive Cancer Center, Duarte, California, 91010-3000, United States;
Recruiting
Marianna Koczywas, MD 626-359-8111
mkocywas@coh.org

City of Hope Medical Group, Pasadena, California, 91105, United States; Recruiting
Mark V. McNamara, MD 626-396-2900
mmcnamara@ccsmg.com

University of California Davis Cancer Center, Sacramento, California, 95817, United States;
Recruiting
David R. Gandara, MD 916-734-3772
dgandara@cc.ucdmc.ucdavis.edu

Illinois
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, 62526, United States;
Recruiting
James L. Wade, MD 217-876-6603

Ingalls Memorial Hospital, Harvey, Illinois, 60426, United States;
Recruiting
Mark F. Kozloff, MD 708-333-2300

LaGrange Memorial Hospital, LaGrange, Illinois, 60525, United States; Recruiting
James E. Hannigan, MD 708-579-3418

Louis A. Weiss Memorial Hospital, Chicago, Illinois, 60640, United States; Recruiting
Gary D. Steinberg, MD 773-564-5272

Loyola University Medical Center, Maywood, Illinois, 60153, United States; Recruiting
Joseph I. Clark, MD 708-327-3236
jclark@lumc.edu

Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, 61602, United States;
Recruiting
James A. Knost, MD, FACP 309-672-5681

University of Chicago Cancer Research Center, Chicago, Illinois, 60637-1470, United States;
Recruiting
Hedy L. Kindler, MD 773-702-0360


Indiana
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, 46601, United States;
Recruiting
David Allen Taber, MD 800-284-7370

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, 46885-5099, United States;
Recruiting
David Frank Sciortino, MD 219-484-8830

Michigan
Lakeland Medical Center - St. Joseph, Saint Joseph, Michigan, 49085, United States;
Recruiting
Eric P. Lester, MD 616-982-4963

New York
Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States;
Recruiting
Lee M. Krug, MD 212-639-8420

Pennsylvania
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, 19104-4283, United States;
Recruiting
James Stevenson, MD 215-662-8756

Texas
University of Texas - MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States;
Recruiting
Charles Lu, MD 713-792-6363

Study chairs or principal investigators
Hedy L. Kindler, MD, Study Chair
University of Chicago Cancer Research Center